Catalyst

Slingshot members are tracking this event:

AbbVie (ABBV) Submits NDA to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ABBV

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 19, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Glecaprevir, Pibrentasvir, Chronic Hepatitis C